Clinically, TAM-targeted therapies could complement existing treatments, with biomarkers like CD163 and IL-10 guiding personalized interventions, ultimately improving tumor control and patient outcomes through optimized multimodal strategies. This evidence concerns the gene CD163 and neoplasm.